GB Sciences Announces Opening of Las Vegas, Nevada, Indoor Cannabis Grow, Moving GB Sciences into a Revenue Generating Stage
GB Sciences cannabis cultivation facility will initially be equipped with 200 grow lights supporting approximately 800 cannabis plants, with an initial production of 115 pounds of cannabis per month and serve the patient population of Nevada. When it's at capacity, the facility will have 1,000 grow lights and 4,000 plants, which are expected to generate over $20 million in revenues per year.
Texas and California and other states GB sciences is looking to break into other states this year.
GB Sciences Files Patent Application for the Treatment of Chronic Arthritis, Crohn’s Disease, Inflammatory Bowel Disease, and Asthma; Proprietary Cannabinoid-Containing Complex Mixtures for the Treatment of Inflammatory Disorders
Growblox Sciences Announces Patent Application for Treatments of Parkinson's Disease, Alzheimer's Disease, Huntington's Disease and Dementia.
Pilot program for Parkinson's to commence in the coming months.
GB Sciences Licenses Patent To Develop New Cannabis-Based Therapies For The Treatment Of Heart Disease
LAS VEGAS, Dec. 13, 2016 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) is pleased to announce that its wholly-owned subsidiary, Growblox Life Sciences, LLC has licensed intellectual property from Makai Biotechnology, LLC. The patent underlying the license was issued by the USPTO in July of 2015, and claims therapeutic methods for the treatment of cardiac hypertrophy and associated pathologies through regulation of the cannabinoid receptor, TRPV1. TRPV1 can be regulated therapeutically by plant-based cannabinoids, which creates a plethora of potentially new therapeutic agents for the treatment of cardiac hypertrophy and heart failure.
This is a huge turn around story. With a small float of 89 Million shares in issuance and less than 7 million floating. 2.1 Cash on hand and less than 700k liabilities.
The combo of growing medical marijuana weed and expanding to other states this year. Is the ultimate combination to generate revenue and expand its bio pharma programs ahead.
